Browsing Category
Pharma Industry News
4721 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Samsung Epis beats growth expectations in Q1 as Bioepis expands global partnerships
Samsung Epis Holdings reported strong Q1 2026 growth. Read how Samsung Bioepis, new partnerships, and pipeline bets could shape what comes next.
What AACR 2026 reveals about immune resistance in triple-negative breast cancer
Find out how CytoDyn Inc.’s AACR 2026 data could reshape TNBC immunotherapy and what it means for investors and the oncology market.
Why TROP2 ADC competition may hinge on payload differentiation after AKTX-101 data
Find out how AKTX-101 could reshape TROP2 ADC competition and what it means for oncology investors and strategy.
Can ODM-212 validate TEAD inhibition as a viable oncology strategy in mesothelioma?
Can Orion Corporation’s ODM-212 prove TEAD inhibition works in mesothelioma? Discover what this FDA orphan designation really signals.
How intranasal neurosteroids may change emergency care timing in mild traumatic brain injury
Can ONP-002 change concussion care timing? Discover how Oragenics, Inc. is targeting early intervention in mTBI treatment.
hVIVO (AIM: HVO) wins world-first Phase III whooping cough challenge trial contract with ILiAD Biotechnologies
hVIVO (AIM: HVO) signs its largest human challenge trial contract with ILiAD Biotechnologies for a world-first pivotal Phase III pertussis vaccine study. Read what it means for investors.
AVCT stock near 52-week high as Avacta Group pre|CISION data challenges Enhertu benchmark at AACR 2026
Avacta Group (AIM: AVCT) AACR 2026 data show AVA6103 outperforms Enhertu on tumor selectivity while AVA6207 delivers first in vivo dual payload results. Read our analysis.
IDEAYA Biosciences (IDYA) stock in focus as ASCO 2026 late-breaker sets up fuller OptimUM-02 readout
IDEAYA Biosciences heads to ASCO 2026 with full OptimUM-02 data. Read why the late-breaking slot could matter for IDYA stock and melanoma strategy.
Why Lilly’s $3.25bn Kelonia acquisition signals a manufacturing shift across the entire CAR-T landscape
Eli Lilly agrees to acquire Kelonia Therapeutics for up to $7B. What the iGPS in vivo CAR-T platform means for oncology and LLY investors. Read the analysis.
Karyopharm Therapeutics (KPTI) tees up ASCO 2026 readout as SENTRY trial shifts myelofibrosis debate
Karyopharm is taking its Phase 3 SENTRY myelofibrosis data to ASCO 2026. Read why the late-breaking slot matters for KPTI and selinexor now.